Skip to main content
. 2014 Oct 29;29(1):140–152. doi: 10.1210/me.2014-1301

Figure 3. BMPR-II and ActR-IIB enhance mutant ALK2 associated with FOP but not mutant ALK2 associated with heart disease.

Figure 3.

A–D, The effects of BMPR-II and ActR-IIB on ALK2 mutants identified in FOP and heart disease patients were examined. The C2C12 cells were cotransfected with 100 ng of an ALK2 vector carrying mutations identified in FOP (A and B) or heart disease patients (C and D) and 100 ng of BMPR-II (A and C) or ActR-IIB (B and D). ALP activity was determined on day 3. The expression levels of mutant ALK2 were determined through a Western blot analysis using antibodies against V5-tag and tubulin. The data are expressed as the mean ± SD (n = 3). *, P < .05 and **, P < .01 vs BMPR-II or ActR-IIB transfected cells (ANOVA).